Healthcare News and Headlines
Healthcare News and Headlines
Healthcare Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
On April 7, 2026, BioWorld reported three notable biotech developments. Jiangsu and Shanghai Hengrui patented novel Nav1.8 sodium‑channel blockers, a potential new class for chronic pain management. Researchers highlighted hematopoietic stem‑cell studies that implicate inflammation as an early driver of leukemia. Infinimmune presented preclinical data showing its anti‑IL‑22 antibody IFX‑101 reduces symptoms in atopic dermatitis models.
BioWorld Asia’s April 7 2026 briefing highlighted three emerging biotech developments. Jiangsu and Shanghai Hengrui patented selective Nav1.8 blockers that deliver strong analgesic effects with minimal off‑target activity, positioning them as potential first‑in‑class chronic pain therapies. New research linked chronic inflammation in...
BioWorld’s April 7 briefing spotlights three notable biotech developments. Researchers at Jiangsu and Shanghai Hengrui have patented selective Nav1.8 sodium‑channel blockers that deliver strong analgesic effects with minimal off‑target activity, opening a potential new class for chronic pain. Parallel studies reveal...
Sononeu, a Boston‑based biotech, secured a $5.2 million grant from the U.S. Advanced Research Projects Agency for Health (ARPA‑H) to advance its ultrasound‑activated therapeutic platform. The award will fund pre‑clinical development of drug‑delivery systems that release payloads only when exposed to...
Jiangsu and Shanghai Hengrui Pharmaceuticals have patented novel Nav1.8 sodium‑channel blockers that selectively target pain signaling, showing strong pre‑clinical analgesic activity with minimal off‑target effects. Parallel research highlights chronic inflammation’s role in reshaping hematopoietic stem cells, creating a microenvironment that...
BioWorld’s April 7, 2026 clinic roundup compiles a broad set of data snapshots, special reports and infographics spanning biopharma, medical technology, and emerging therapeutic areas. The collection links to analyses on M&A activity, GLP‑1 developments in China, mRNA vaccine research, pulsed‑field ablation...
A cyberattack on Signature Healthcare Brockton Hospital in Massachusetts forced the facility to turn away ambulances and activate downtime procedures, cancelling chemotherapy infusions while keeping emergency rooms and surgeries operational. The hospital is working with external experts to restore systems,...
Vernacare, backed by private equity firm H.I.G., announced the acquisition of Eakin Surgical, a UK manufacturer of single‑use surgical instruments and procedure solutions. The deal adds a proven line of disposable tools to Vernacare’s existing portfolio, strengthening its foothold in...
Medicare Advantage enrollment, once a growing staple, saw a sharp reversal in 2026 as nearly 3 million seniors were forced to leave their plans. Disenrollment rates surged to 10% of beneficiaries, driven by insurers exiting counties due to rising medical costs...
ARPA-H announced a $100 million program to fund clinical trials for joint regeneration. Three leading academic centers were selected to test innovative therapies aimed at repairing and regrowing damaged cartilage and bone. The projects will explore senolytic drugs, engineered tissue scaffolds,...
Gilead Sciences announced a deal to acquire German biotech Tubulis for $3.15 billion upfront, potentially rising to $5 billion with milestones. The purchase adds a next‑generation antibody‑drug conjugate (ADC) platform and two clinical candidates, TUB‑040 and TUB‑030, to Gilead’s oncology pipeline. This...
Merck agreed to acquire Terns Pharmaceuticals for $6.7 billion, a price roughly 13% lower than its initial offer after new clinical data raised concerns. The renegotiated deal reflects the impact of late‑stage trial results on valuation in the biotech M&A wave....
Novo Nordisk has introduced a high‑dose 7.2 mg version of its obesity drug Wegovy in the United States, expanding the GLP‑1 portfolio beyond the standard 2.4 mg dose. The new formulation targets patients with severe obesity who need greater weight‑loss efficacy. Pricing...
Houston Methodist has partnered with Midstream Health to roll out its Agentic AI Financial Action Platform across the health system, beginning with supply‑chain operations. The AI agents ingest both structured ERP data and unstructured contract PDFs to automatically detect pricing...
Robin Weiss, a pioneering virologist who died at 86, led the 1984 discovery that CD4 is the cellular receptor for HIV and created the first UK HIV antibody test with Richard Tedder. The test enabled large‑scale, accurate detection of HIV,...
Irish engineer Aonghus O’Donovan has launched the MyCelsius cooling bracelet, a wrist‑worn device that drops skin temperature by 10 °C in under ten seconds. The wearable, entering the Irish market on April 7, targets menopausal hot flushes and claims an 80% efficacy...
Researchers demonstrated that enhancing the brain's glymphatic waste‑clearance system can remove a migraine‑triggering chemical in mice, reducing facial pain symptoms. The approach repurposes a hypertension drug to boost clearance, offering a potential therapy for the one‑third of migraine sufferers who...
Jiangsu and Shanghai Hengrui have patented selective Nav1.8 blockers that demonstrate potent pre‑clinical analgesic activity for chronic neuropathic pain. New research links chronic inflammatory signaling to early leukemic transformation in hematopoietic stem cells, suggesting anti‑inflammatory approaches could intervene before disease...
Biopharma financing in 2026 surged to $25.1 billion, almost twice the amount raised in 2025. The jump reflects a wave of venture‑capital commitments, a robust IPO market, and heightened merger‑and‑acquisition activity. Public offerings alone added roughly $8 billion, while private rounds supplied...
Genomic sequencing, a key component of precision oncology, is underused in metastatic cancer care. A JAMA Network Open study of five cancer types found that only about half of patients received tumor genetic testing, with lower rates among low‑income, Medicare/Medicaid,...
Researchers at Jiangsu and Shanghai Hengrui have patented selective Nav1.8 sodium‑channel blockers that alleviate pain in rodent models without cardiac or CNS effects, and plan IND‑enabling toxicology studies in 2026 with Phase I trials slated for 2027. Parallel advances in hematopoietic...
Recent hematopoietic stem cell (HSC) studies reveal that chronic inflammation can seed the earliest genetic lesions that later evolve into leukemia. The research shows that inflammatory signals remodel the bone‑marrow niche, prompting mutations in primitive stem cells long before clinical...
Hong Kong’s Hospital Authority terminated Dr. Jensen So’s contract after he posted an Instagram story showing a resuscitation procedure in a public ward. The authority said the doctor breached the professional code of conduct, lacked integrity and compromised patient privacy. The...
Gilead announced a deal to acquire German ADC specialist Tubulis for up to $5 bn, with $3.15 bn paid upfront and up to $1.85 bn in milestones. The transaction, slated to close in Q2 2026, brings Tubulis' lead candidate TUB‑040—a NaPi2b‑directed topoisomerase‑I inhibitor in...
The U.S. Food and Drug Administration has granted an investigational device exemption (IDE) for TRiCares' Topaz transcatheter tricuspid valve replacement system, allowing a pivotal randomized trial across the United States, Canada, and Europe. The study will involve up to 75...
The University of Washington expanded its Health Care Alternative Spring Break program to include pre‑med students shadowing emergency medical services at Longview Fire Department. In 2024, 82% of the department’s calls were medical, underscoring the relevance of pre‑hospital experience. Students...
Healthcare stocks are gaining momentum as the Centers for Medicare & Medicaid Services signaled higher Medicare Advantage payment rates for 2027. The prospect of increased reimbursements is boosting profit outlooks for managed‑care providers, with CVS Health rallying 4.5% after the...
The article argues that healthcare revenue‑cycle partners must shift from reactive "tell us what you need" approaches to proactive, anticipatory support. Operators juggling access, staffing, patient experience, and finances often lack the bandwidth to articulate needs during crises. By identifying...
HexemBio announced a $10.4 million seed round, led by Draper Associates with participation from SOSV, Seraphim and other investors. The biotech is developing a Synthetic Human Yolk Sac that temporarily houses a patient’s blood stem cells to rejuvenate their function before...
SimpliFed announced a $10.8 million Series A round led by Morningside and Hesperia Capital to broaden its virtual maternal‑health platform beyond breastfeeding support. The capital will fund a proprietary Maternal Health Operating System that integrates with electronic medical records, enabling seamless data...
A new JAMA Psychiatry study shows the antidepressant mirtazapine can modestly reduce methamphetamine use. In the double‑blind Tina Trial, 339 Australian participants received either 30 mg daily mirtazapine or placebo for 12 weeks. Those on mirtazapine cut meth use by an...
PharmaForce has named Lynn Eschenbacher, PharmD, MBA, FASHP, as its new Chief Pharmacy and Strategy Officer to steer the company’s 340B program strategy. Eschenbacher brings over 25 years of pharmacy leadership across major health systems, most recently at Quva Pharma. The...
Medication non‑adherence still costs U.S. drug makers roughly $250 billion a year, despite billions spent on marketing. Independent pharmacies, which patients visit nearly twice as often as primary‑care doctors, are emerging as a critical touchpoint as chain stores close. New pharmacy‑focused...
Humira, AbbVie’s adalimumab used by over 300,000 Americans, continues to dominate the market even after its patent expired, keeping prices sky‑high. The drug’s outsized share illustrates systemic flaws in U.S. pharmaceutical distribution, where limited biosimilar competition and opaque pricing inflate...
Brockton Hospital in Massachusetts is diverting ambulances and cancelling certain services after a cybersecurity incident disrupted its information systems. Chemotherapy infusions and retail pharmacies were suspended, while inpatient and walk‑in emergency care remain operational. The hospital reverted to paper records...
Maven Clinic has teamed up with caregiving platform Wellthy to deliver an integrated family‑care benefit for employers. The joint solution merges Maven’s virtual women’s and family health services with Wellthy’s care‑coordination and backup‑care logistics, targeting the “sandwich generation” of workers...
The FDA, leveraging the Trump administration’s budget, unveiled proposals to boost domestic drug development and manufacturing, including streamlined early‑stage trials and a rule letting U.S. generic makers challenge brand patents a month before foreign competitors. Commissioner Marty Makary framed the...
March 2026 saw a surge of biosimilar activity, highlighted by Celltrion’s launch of Remsima IV in the EU and Avtozma SC in the United States, expanding both IV and sub‑cutaneous options for infliximab and tocilizumab. Samsung Bioepis inked a global...
In 2025, U.S. contract manufacturing deals for FDA‑approved drugs fell sharply, while Europe recorded more than three times the U.S. volume. Despite a 15% U.S. tariff on EU pharmaceuticals, major U.S. firms such as Johnson & Johnson and Vertex invested...
The White House’s FY 2027 budget request allocates $5.1 billion to global health, a modest increase over the previous year but far below the $9.4 billion Congress approved for FY 2026. The proposal cuts funding for the World Health Organization, the Pan‑American Health Organization,...
Samsung upgraded its Galaxy XR headset with Android Enterprise support and Samsung Knox Manage integration, aiming at healthcare deployments. The enhancements let hospital IT departments manage the headsets like smartphones, applying data policies, network configurations, and remote lock or wipe functions....
Northern Ireland has passed legislation granting statutory miscarriage leave, allowing employees up to five days of paid time off after a miscarriage. The measure aligns the region with England and Wales, which introduced similar provisions last year. Employers will treat...
Digital health tools have long suffered from gender bias because training data and clinical trials underrepresent women. The Consumer Technology Association (CTA) has introduced the first ANSI‑accredited women’s health standard, giving developers a concrete framework for inclusive design, testing, and...
HexemBio announced a $10.4 million seed round led by Draper Associates to develop a blood‑stem‑cell rejuvenation therapy built on its Synthetic Human Yolk Sac platform. The technology temporarily places a patient’s own haematopoietic cells into a recreated embryonic niche, then returns...
Medline (Nasdaq: MDLN) has launched Pick Pack Pro™, an automated fulfillment system at its Montgomery, N.Y., distribution center. The technology combines robotics, conveyor sortation and right‑size packaging to handle high‑volume, narrow‑catalog orders for health plan members. By optimizing order batching...
EQT Life Sciences has exited its minority stake in Tubulis, the German clinical‑stage biotech developing next‑generation antibody‑drug conjugates, selling the position to Gilead Sciences. The transaction adds a promising ADC platform to Gilead’s oncology portfolio. In a separate deal, private‑equity...
Cell and gene therapy is transitioning from ex vivo manufacturing toward in vivo delivery, driven by advances in vector engineering and lipid‑nanoparticle platforms. Major pharma players have launched billion‑dollar acquisitions to secure in vivo CAR‑T and RNA technologies, while the stem‑cell market is...
Researchers at Jiangsu and Shanghai Hengrui have patented Nav1.8 blockers that deliver strong analgesic effects while sparing off‑target channels, opening a new avenue for chronic pain therapy. Parallel studies reveal that chronic inflammation can reprogram hematopoietic stem cells, driving early...
Vertex Pharmaceuticals has filed a patent covering a new series of orexin OX2‑receptor agonists, marking the company’s first public foray into sleep‑modulating therapeutics. The disclosed molecules feature distinct heterocyclic cores and enhanced blood‑brain barrier penetration, aiming for improved potency and...
Jiangsu and Shanghai Hengrui Pharmaceuticals have patented selective Nav1.8 sodium‑channel blockers that demonstrate potent analgesic effects with minimal off‑target activity, opening a new avenue for chronic pain treatment. Parallel research highlights how chronic inflammation reshapes the bone‑marrow microenvironment, driving hematopoietic...
